Mitral Valve Prolapse (MVP) - France Study

Genetic Polymorphisms in Idiopathic Mitral Valve Prolapse :A French Prospective Study Using a Genome Wide Analysis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00799565

Acronym

MVP-France

Enrollment

1179

Registered

2008-12-01

Start date

2008-12-31

Completion date

2011-07-31

Last updated

2011-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitral Valve Prolapse

Keywords

Mitral Valve prolapse, echography, genetic study, study case-witness, Patients with a Mitral Valve Prolapse

Brief summary

This prospective nation-wide (France) study aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects.

Detailed description

Two MVP populations will be defined in that study, either with the classical Barlow (myxomatous) disease or the fibroelastic degenerescence (thin and redundant leaflets). MVP adult patients (\> 18 year-old) will be included if they present the following 1) or 2) criteria : 1. 2D-echocardiographic mitral leaflet prolapse on the parasternal long-axis view \> 2 mm AND leaflet thickness \> 4 mm or mitral regurgitation \> 2 + (using color Doppler) 2. Previous surgery for pure severe mitral regurgitation due to MVP with Barlow disease or fibroelastic degenerescence (with operative report available) Patients will be excluded in case of associated heart disease (hypertrophic cardiomyopathy, rheumatismal disease…) or syndromic disease (Marfan, Ehlers-Danlos…). Around 30 (cardiology, cardiovascular surgery) french centers will participate to this study. An e-CRF will be used to collect clinical data. A genetic core lab will collect the DNA samples. An echocardiographic core lab will collect and read all the echo recordings. DNA analysis will be compared between the patient group and spouses of the patients used as controls. In case of inadequacies concerning group size or age, available genotyped cohorts will be used.

Interventions

GENETICcatch of blood

4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it. This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for MVP patients : * Male or female subject ≥18 years * Affiliation to the French social insurance system * Written informed consent * Idiopathic MVP defined by the presence of criteria 1) and 2) OR of criterion 3) : 1. Echographic MVP \> 2 mm on the left ventricular parasternal long-axis view 2. Echographic myxomatous valve (thickness \> 4 mm) or significant mitral regurgitation (\> 2 + using color Doppler) 3. History of mitral valve surgery for pure mitral regurgitation due to MVP (myxomatous or fibroelastic deficiency) with available detailed operative report.

Exclusion criteria

: * Presence of heart disease causing MVP (rheumatic, HCM…) * Syndromic disease (Marfan, Ehlers-Danlos…) Inclusion criteria for healthy subject : * Male or female subject ≥40 years * Absence of MVP or absence of mitral valve dystrophy * Caucasian

Design outcomes

Primary

Measure	Time frame
Genetic polymorphism identification	Day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026